Recently, therapeutic or preventive effects of glucagon-like peptide-1 (GLP-1) agonists or sodium glucose cotransporter-2 (SGLT-2) inhibitors for NAFLD have been actively studied11–14, but they have not yet been recognized as a formal option for NAFLD treatment. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.